Psoriasis poses a significant economic burden. A systematic review of psoriasis treatments cost and effectiveness has been performed extensively in the United States (US) and Europe, but such review is limited in Asia. This review aims to analyze all previous literature on the cost and effectiveness of systemic and biological treatment for moderate to severe psoriasis. Cost of illness and cost-effectiveness studies that examined the economic burden, cost, and effectiveness of psoriasis treatments (systemic and biological) in Asian region from 2010 to 2020 were published in English language. All costs were converted into 2020 US Dollar. All COIs included found that direct medical costs were greater than indirect costs. Adalimumab, ustekinumab, risankizumab, secukinumab 150 mg were cost-effective treatments and of the lowest cost per PASI-75/PASI1 and/or QALY. When comparing the different treatments, topical and systemic psoriasis treatments were observed to be the most cost-effective compared with other modalities. Given the tremendous economic effects of psoriasis on patients and hospitals, economic analysis, clinicians, and policymakers should consider cost and effectiveness evidence, as this systematic literature review was conducted to analyze previous documentation regarding the cost and effectiveness of systemics and biologics in Asian countries.

Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients.Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done.Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits.Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

/pdf/cost-of-illness-in-psoriasis-patients-on-bath-puva-therapy-u43of7yy5e.pdf

Anantha Naik Nagappa

Papers

Cost of illness in Psoriasis Patients on Bath PUVA therapy Versus Methotrexate